Digital Therapeutics

About 2% of global population suffers from OCD, of which only about 10% are receiving treatment

OC Free™


Investigational SaMD for contamination OCD*

*Obsessive Compulsive Disorder

Among CBT*, ERP** is first-line treatment for OCD, however, only 50% experience an improvement in OCD symptoms and the dropout rate is about 25%


*Cognitive Behavioral Therapy

**Exposure and Response Prevention

OC Free™ not only improves the accessibility and effectiveness of existing OCD treatments, but enhances the QOL* of patients through digitalized ERP treatment

*Quality of Life

Development Status

Stage 1....  

Domestic Pilot study....

Stage 2

US Pilot study

.....Stage 3

.....US Pivotal study


BIXINK strives to be a pioneer in developing Korea's first FDA-approved digital therapeutics, and is currently pursuing pilot study in the United States

l OC Free™ l


Computerized Behavioral Therapy Device for OCD

CAUTION: Investigational Device.

Limited by Federal law to investigational use.


OC Free™

Development

Timeline



*FDA Approval Target 2025

Copyright 2021 - BIXINK │ Terms of Use │ Contact │ Privacy

6F, 292 Gangnam-daero, Gangnam-gu, Seoul 06258, Republic of Korea